- Home
- FVCB vs ACIU Comparison
FVCB vs ACIU Comparison
Compare FVCB & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FVCB
- ACIU
- Stock Information
- Founded
- FVCB 2007
- ACIU 2003
- Country
- FVCB United States
- ACIU Switzerland
- Employees
- FVCB N/A
- ACIU N/A
- Industry
- FVCB Major Banks
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- FVCB Finance
- ACIU Health Care
- Exchange
- FVCB Nasdaq
- ACIU Nasdaq
- Market Cap
- FVCB 204.0M
- ACIU 213.3M
- IPO Year
- FVCB N/A
- ACIU 2016
- Fundamental
- Price
- FVCB $12.83
- ACIU $2.13
- Analyst Decision
- FVCB Buy
- ACIU Strong Buy
- Analyst Count
- FVCB 1
- ACIU 1
- Target Price
- FVCB $16.00
- ACIU $12.00
- AVG Volume (30 Days)
- FVCB 35.8K
- ACIU 160.7K
- Earning Date
- FVCB 07-22-2025
- ACIU 08-05-2025
- Dividend Yield
- FVCB 1.87%
- ACIU N/A
- EPS Growth
- FVCB 359.39
- ACIU N/A
- EPS
- FVCB 1.11
- ACIU N/A
- Revenue
- FVCB $62,780,000.00
- ACIU $36,362,036.00
- Revenue This Year
- FVCB $12.99
- ACIU N/A
- Revenue Next Year
- FVCB $7.26
- ACIU $533.21
- P/E Ratio
- FVCB $11.57
- ACIU N/A
- Revenue Growth
- FVCB 40.73
- ACIU 86.71
- 52 Week Low
- FVCB $9.49
- ACIU $1.43
- 52 Week High
- FVCB $14.50
- ACIU $3.98
- Technical
- Relative Strength Index (RSI)
- FVCB 51.59
- ACIU 48.82
- Support Level
- FVCB $12.25
- ACIU $2.05
- Resistance Level
- FVCB $13.39
- ACIU $2.25
- Average True Range (ATR)
- FVCB 0.37
- ACIU 0.17
- MACD
- FVCB -0.01
- ACIU -0.02
- Stochastic Oscillator
- FVCB 50.88
- ACIU 19.57
About FVCB FVCBankcorp Inc.
FVCBankcorp Inc is a registered bank holding company. It operates through the sole subsidiary, FVCbank which is a community-oriented, locally-owned, and managed commercial bank. It offers commercial banking services to small and medium-sized businesses, professionals, non-profit organizations and associations, and investors. It also provides retail banking services to accommodate the individual needs of both corporate customers as well as the communities it serves. The bank provides other facilities such as online banking, mobile banking, remote deposit service, and lending products, among others. Its primary source of revenue is the net interest income.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.